// App-Quantinova.ai

3701 : Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Researchers

Presenter

  • Sally Arai

Principal Investigators

  • Nancy L Bartlet

  • Bruce D. Cheson

  • Andres Forero-Torres

  • Craig H. Moskowitz

  • Joseph M. Connors

  • Michelle A. Fanale

  • Sven De Vos

  • Andreas Engert

  • Tim Illidge

  • Peter Borchmann

  • Ajay K. Gopal

  • Franck Morschhauser

  • Sandra J. Horning

  • Anas Younes

  • Lei Feng

  • Ying Yuan

  • Scott E. Smith

  • Stephen M. Ansell

  • Joseph D Rosenblatt

  • Kerry J. Savage

  • Radhakrishnan Ramchandren

Medical Centers

  • Hematology, CHRU Lille, Lille, France

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • First Department of Internal Medicine, German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, Germany

  • The Christie Hospital, Manchester, United Kingdom

  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

Locations

  • Canada

  • Germany

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

Outcome

  • N/A

Study Design

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved